芳香化酶抑制剂的耐药机制及对策  

Aromatase inhibitors resistance:mechanism and strategies to reverse the resistance

作　　者：陈蕊华[1] 张凤春[1] 

机构地区：[1]上海交通大学医学院附属仁济医院肿瘤内科,上海200127

出　　处：《现代肿瘤医学》2008年第7期1231-1233,共3页Journal of Modern Oncology

基　　金：国家自然科学基金(编号:30171064)

摘　　要：芳香化酶抑制剂(aromatase inhibitors,AIs)在绝经后激素反应性乳腺癌妇女的辅助内分泌治疗和解救治疗效果优于三苯氧胺(tamoxifen,TAM)。然而,随着药物治疗的深入,AIs的耐药也逐渐显现。近年研究发现:AIs的原发耐药可能与芳香化酶基因多态性有关,但具体的原理还不甚清楚。AIs的继发耐药可能与雌激素受体(ER)和多个生长因子通路的交叉通话相关。针对AIs的耐药,许多学者进行了逆转耐药的研究,本文就AIs的原发与继发耐药机制及逆转耐药的策略进行综述。It has been demonstrated that aromatase inhibitors （AIs） therapy is much more effective than tamoxifen （TAM） in the treatment of hormone - dependent breast cancer. Even though, resistance to these endocrine therapies still occurs. Studies concerning resistance meehanisms showed： resistance might be associated with genetic pelymorphisms in the human aromatase gene. Yet the precise mechanism to AIs resistance is not completely understood. The mechanism of acquired resistance might results from cross - talk between ER and growth factor pathways, or other currently unidentified pathways. Now we review the research on mechanism of AIs resistance.

关 键 词：乳腺癌 芳香化酶抑制剂 内分泌耐药 逆转耐药 

分 类 号：R730.53[医药卫生—肿瘤]